Interpace Biosciences, Inc. Common Stock
IDXG
IDXG was delisted on the 24th of February, 2021.
13 hedge funds and large institutions have $2.37M invested in Interpace Biosciences, Inc. Common Stock in 2017 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 7 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
59% more capital invested
Capital invested by funds: $1.49M → $2.37M (+$879K)
24% less funds holding
Funds holding: 17 → 13 (-4)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$1.27M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$81.1K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$69.5K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$36.5K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$30.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$646K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$476K |
| 3 |
WS
Wedbush Securities
Los Angeles,
California
|
-$44.3K |
| 4 |
Bank of New York Mellon
New York
|
-$18K |
| 5 |
AA
Ancora Advisors
Cleveland,
Ohio
|
-$13K |
IDXG Hedge Fund Activity: Q3 2017 in Review
13 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Interpace Biosciences, Inc. Common Stock (IDXG) for Q3 2017, worth a combined $2.37M — up 59% from $1.49M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of IDXG and 4 opened new positions — a net loss of 3 holders — while 2 trimmed existing stakes and 5 added.
The largest buyer was BlackRock, adding an estimated $1.27M. The largest seller was Susquehanna International Group, exiting entirely with an estimated $646K sold.
- 13 institutional investors held Interpace Biosciences, Inc. Common Stock (IDXG) as of Q3 2017, down from 17 in Q2 2017.
- Funds reported $2.37M of Interpace Biosciences, Inc. Common Stock stock for Q3 2017, up 59% quarter-over-quarter.
- 4 funds opened new Interpace Biosciences, Inc. Common Stock positions in Q3 2017 and 7 closed out, a net change of -3 holders.
- The largest Interpace Biosciences, Inc. Common Stock buyer in Q3 2017 was BlackRock, an estimated $1.27M added.
- The largest Interpace Biosciences, Inc. Common Stock seller in Q3 2017 was Susquehanna International Group, an estimated $646K sold.
Based on aggregated 13F filings for Q3 2017.